GlassScriptPhysician profile
Jennifer John Oconnell
NPI 1578635678
$1,250.56
in general payments reported to CMS, 2019-2025
15 companies · $146 in 2025
The $146 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.58 · 2020: $46.66 · 2021: $85.82 · 2022: $194 · 2023: $135 · 2024: $572 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $853.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $853.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stratus Medical, LLC | $492.09 | 2023-2025 | Nimbus |
| Acadia Pharmaceuticals INC | $253.56 | 2024 | Nuplazid |
| Abbott Laboratories | $125.46 | 2022 | |
| Neurocrine Biosciences, INC. | $68.83 | 2022-2023 | Ongentys, Ingrezza |
| Lundbeck LLC | $58.96 | 2019-2021 | |
| Nevro Corp. | $53.95 | 2019-2022 | |
| Relievant Medsystems, INC. | $39.53 | 2023 | Intracept |
| Ucb, INC. | $26.53 | 2020 | |
| Genentech USA, INC. | $24.31 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $20.69 | 2019 | |
| Aquestive Therapeutics, INC. | $20.13 | 2020 | |
| Kci USA, INC. | $18.57 | 2021 | |
| Avanir Pharmaceuticals, INC. | $16.95 | 2019 | |
| Alexion Pharmaceuticals, INC. | $16.04 | 2022 | |
| Piramal Critical Care | $14.96 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Oconnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.